Last €68.24 EUR
Change Today +0.85 / 1.26%
Volume 339.9K
UCB On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
OTC US
Frankfurt
As of 11:35 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

ucb sa (UCB) Snapshot

Open
€67.44
Previous Close
€67.39
Day High
€68.30
Day Low
€67.35
52 Week High
08/29/14 - €75.62
52 Week Low
04/11/14 - €54.53
Market Cap
13.3B
Average Volume 10 Days
403.4K
EPS TTM
€0.60
Shares Outstanding
194.5M
EX-Date
--
P/E TM
113.7x
Dividend
€1.06
Dividend Yield
1.52%
Current Stock Chart for UCB SA (UCB)

Related News

No related news articles were found.

ucb sa (UCB) Related Businessweek News

No Related Businessweek News Found

ucb sa (UCB) Details

UCB S.A., a global biopharmaceutical company, focuses on central nervous system disorders and immunology diseases. The company’s core products include Cimzia for inflammatory arthritis indications and Crohn’s disease; Vimpat for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for cognitive disorders; and Omeprazole for hyperacidity diseases. The company is also developing Vimpat for epilepsy partial-onset seizures (POS)/monotherapy, epilepsy POS/pediatric adjunctive therapy, and epilepsy primary generalized tonic clonic seizures/adjunctive therapy; brivaracetam as adjunctive therapy for epilepsy; and tozadenant for Parkinson’s disease. Its products under development also comprise Cimzia for axial spondyloarthritis and juvenile idiopathic arthritis; epratuzumab for systemic lupus erythematosus; romosozumab for post-menopausal osteoporosis; CDP7657 for systemic lupus erythematosus; and UCB4940, UCB5857, and UCB7665 for immunological diseases. The company has collaborations with ConfometRx, Five Prime Therapeutics, CRELUX and 4SC Discovery, The Lieber Institute For Brain Development, Neuropore Therapies Inc., and Biogen Idec. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,535 Employees
Last Reported Date: 02/28/15
Founded in 1928

ucb sa (UCB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ucb sa (UCB) Key Developments

UCB Announces Earnings Results for the Financial Year 2014; Provides Earnings Guidance for the Year 2015

UCB announced earnings results for the financial year 2014. For the year, the company reported that revenues increased by 7% year on year (y/y) on a reported basis to EUR 3.3 billion. Net sales were up 5% y/y to EUR 2.9 billion. In particular, the company's core product portfolio - Cimzia (certolizumab), Vimpat (lacosamide), and Neupro (rotigotine) accounted for 50% of overall company sales and boosted company performance by bringing combined sales growth of 24% y/y, edging up to EUR 1.5 billion. The company provided earnings guidance for the year 2015. Looking at the financial outlook published by the company, the firm is confident that the core portfolio of products will continue to deliver sustained growth in 2015. In particular, the company forecasted achieving revenues of approximately EUR 3.55 billion to EUR 3.65 billion. Furthermore, recurring EBITDA is expected to attain EUR 710 million to -740 million.

UCB S.A., 2014 Earnings Call, Feb 27, 2015

UCB S.A., 2014 Earnings Call, Feb 27, 2015

UCB S.A. Announces Positive Results from Two Phase III Parkinson's Disease Studies

UCB S.A. has announced positive results from two Phase III studies evaluating Neupro, or rotigotine transdermal patch, in the treatment of patients in China with early- and advanced-stage idiopathic Parkinson's disease. Results from the Phase III study in patients with early-stage Parkinson's disease demonstrated that rotigotine transdermal patch significantly improved symptoms when compared to placebo. In addition, data from the Phase III study in advanced Parkinson's disease showed that patients treated with rotigotine had a significantly greater decrease in their 'off' time, or periods of poor mobility, slowness and stiffness, compared to those patients taking placebo. The adverse event profile observed in these studies and in this Chinese population were consistent with that known for rotigotine. One of the two Phase III studies was a multicenter, randomized, double-blind, parallel-group, placebo-controlled, 24-week study that evaluated the efficacy and safety of rotigotine (escalating weekly dose starting with daily doses of 2 mg/24 hours to 8 mg/24 hours) in 247 adult patients (30 years and older) with early-stage idiopathic Parkinson's disease. The primary efficacy variable was the change in the sum of the score from the Activities of Daily Living scale and motor examination in the Unified Parkinson's Disease Rating Scale (UPDRS) from baseline to the end of the maintenance period. The second Phase III study was a multicenter, randomized, double-blind, parallel-group, placebo-controlled, 12-week study that evaluated the efficacy and safety of rotigotine (escalating weekly dose starting with daily doses of 4 mg/24 hours to 16 mg/24 hours) in 346 adult patients (30 years and older) with advanced-stage idiopathic Parkinson's disease who were not well-controlled on levodopa.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCB:BB €68.24 EUR +0.85

UCB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $85.65 USD -0.23
Grifols SA €35.78 EUR +0.59
Hospira Inc $87.95 USD +0.24
Sigma-Aldrich Corp $138.13 USD -0.07
Valspar Corp/The $86.94 USD -0.32
View Industry Companies
 

Industry Analysis

UCB

Industry Average

Valuation UCB Industry Range
Price/Earnings 100.0x
Price/Sales 3.6x
Price/Book 2.4x
Price/Cash Flow 57.9x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit www.ucb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.